{"id":212,"date":"2020-03-31T17:29:55","date_gmt":"2020-03-31T21:29:55","guid":{"rendered":"http:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=212"},"modified":"2020-04-01T09:53:14","modified_gmt":"2020-04-01T13:53:14","slug":"fda-virtual-town-hall-for-laboratories-and-manufacturers-developing-diagnostics-tests-for-covid-19","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2020\/03\/31\/fda-virtual-town-hall-for-laboratories-and-manufacturers-developing-diagnostics-tests-for-covid-19\/","title":{"rendered":"FDA Virtual Town Hall for Laboratories and Manufacturers Developing Diagnostics Tests for COVID-19"},"content":{"rendered":"<p>FDA is hosting a virtual town hall April 1, 2020, at 12:15 p.m. Eastern for clinical laboratories and commercial manufacturers developing diagnostic tests for the COVID-19 virus. FDA intends to help answer technical questions about validation and development of tests and FDA\u2019s recently issued Guidance from March 16, 2020 outlining FDA policy for development of diagnostic tests during the COVID-19 public health emergency.\u00a0 FDA will host subsequent virtual town halls for clinical laboratories and commercial manufacturers each Wednesday of April at 12:15 p.m. Eastern. Registration not required. Details to join the call are available on the <a href=\"https:\/\/www.fda.gov\/medical-devices\/workshops-conferences-medical-devices\/virtual-town-hall-series-immediately-effect-guidance-coronavirus-covid-19-diagnostic-tests-04012020\" target=\"_blank\" rel=\"noopener noreferrer\">event page<\/a>.<\/p>\n<p>For additional information, please contact\u00a0<a title=\"Dana J. Ash\" href=\"https:\/\/www.duanemorris.com\/attorneys\/danajash.html\">Dana J. Ash<\/a>,\u00a0<a title=\"Frederick R. Ball\" href=\"https:\/\/www.duanemorris.com\/attorneys\/frederickrball.html\">Frederick R. Ball<\/a>,\u00a0<a title=\"Patrick C. Gallagher, Ph.D.\" href=\"https:\/\/www.duanemorris.com\/attorneys\/patrickcgallagher.html\">Patrick C. Gallagher, Ph.D.<\/a>,\u00a0<a title=\"Jonathan Lourie\" href=\"https:\/\/www.duanemorris.com\/attorneys\/jonathanlourie.html\">Jonathan Lourie<\/a>,\u00a0<a title=\"Vicki G. Norton, Ph.D.\" href=\"https:\/\/www.duanemorris.com\/attorneys\/vickignorton.html\">Vicki G. Norton, Ph.D.<\/a>, or <a title=\"Sandra G. Stoneman\" href=\"https:\/\/www.duanemorris.com\/attorneys\/sandragstoneman.html\">Sandra G. Stoneman<\/a> of Duane Morris&#8217; <a href=\"https:\/\/www.duanemorris.com\/practices\/life_sciences_medical_technologies.html\" target=\"_blank\" rel=\"noopener noreferrer\">LIfe Sciences Industry Group<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA is hosting a virtual town hall April 1, 2020, at 12:15 p.m. Eastern for clinical laboratories and commercial manufacturers developing diagnostic tests for the COVID-19 virus. FDA intends to help answer technical questions about validation and development of tests and FDA\u2019s recently issued Guidance from March 16, 2020 outlining FDA policy for development of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2020\/03\/31\/fda-virtual-town-hall-for-laboratories-and-manufacturers-developing-diagnostics-tests-for-covid-19\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;FDA Virtual Town Hall for Laboratories and Manufacturers Developing Diagnostics Tests for COVID-19&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[430,437,429,447,29,446],"ppma_author":[521],"class_list":["post-212","post","type-post","status-publish","format-standard","hentry","category-general","tag-coronavirus","tag-covid-testing","tag-covid-19","tag-event","tag-fda","tag-virtual-town-hall"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=212"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/212\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=212"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}